LE

Lilly Endowment INC

Concentrated strategySector-focusedLong-term holder

Total reported value

$84.5B

Reporting period: 2026-03-31 · Number of holdings: 1

LILLY ENDOWMENT INC disclosed 1 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $84.5B and a quarterly turnover rate of 15.9%.

Browse other institutions with $10B to $100B AUMBrowse other institutions starting with "L"

Personality snowflake

Concentration
100
Portfolio Stability
15.85
Momentum/Contrarian
50
Sector conviction
100
Diversification
2
Sizing Uniformity

Recent moves

  • Unchanged LLY

    -0.3% -$14.6B

Holdings Map

New buyAddUnchangedTrim

Institutional Game-State Analysis

Core Intent

LILLY ENDOWMENT INC trimmed its sole holding LLY while keeping portfolio weight pinned at 100% — this is profit-taking within a singular conviction, not a reduction of the thesis. The endowment is reducing absolute exposure to lock in gains on an overweight winner, yet refuses to dilute the concentrated bet that generated the returns.

Macro & Fundamentals

The portfolio's exclusive Health Care stance is a bet on the GLP-1 obesity drug cycle and the pricing power of branded pharma. The trim signals the institution is pricing in peak multiples or near-term revenue deceleration, anticipating a regime shift from rapid expansion to maturation. The opposing thesis: regulatory risk on drug pricing or a competitor pipeline breakthrough that erodes LLY's market share.

Blind Spots / Risks

The single-stock structure creates pure idiosyncratic asymmetry — any clinical trial miss or regulatory setback for LLY's key assets (tirzepatide) forces a portfolio liquidation event. The trim reduces absolute exposure but does nothing to hedge the binary outcome. Moreover, as LLY has been a crowded hedge fund long, a coordinated unwind could accelerate losses well beyond any fundamental trigger.

The above is AI-generated from public regulatory filings and summarizes historical data only. It is not investment advice.

Top 10 holdings by weight

Full holdings list this quarter

#TickerIssuerAsset SubclassWeightWeight ChangeShares Change4Q Trend
1LLYEli Lilly & CoStock-Healthcare100.00%-0.32%

Holding changes this quarter

Lilly Endowment INC's most significant position changes for 2026-03-31: Trim: Eli Lilly & Co (LLY) — shares -0.32%.

Position changes disclosed by Lilly Endowment INC for the quarter ending 2026-03-31, including ticker, issuer, weight change, shares change, and action
#TickerIssuerWeight ChangeShares ChangeAction
1LLYEli Lilly & Co-0.32%Trim

FAQ

What is Lilly Endowment INC and what type of investor is it?
Lilly Endowment INC is a investment manager that files SEC Form 13F quarterly, disclosing its U.S. public equity holdings to regulators. As of the most recent reporting period (2026-03-31), the firm manages a tracked equity portfolio valued at approximately $84.5B, spread across 1 disclosed positions.
What are Lilly Endowment INC's largest equity positions?
Based on the latest 13F filing, Lilly Endowment INC's top holdings by market value are: 1. Eli Lilly & Co (LLY) — $84.5B (100.0%)
What changes did Lilly Endowment INC make in its most recent portfolio filing?
In the latest quarter, Lilly Endowment INC took a more defensive posture — trimming 1 positions and completely exiting 0 holdings. The largest of these moves: Trim: Eli Lilly & Co (LLY) — shares -0.32%
What sectors does Lilly Endowment INC focus on?
Lilly Endowment INC is concentrated in the following sectors based on its current disclosed equity portfolio: • Health Care: 100.0%